Diagnostic and Prognostic Significance of Serum "Neutrophil Gelatinase-Associated Lipocalin" in Patients with Colorectal Cancer

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000849695

Acronym

CRC-NGAL

Enrollment

Registered

2014-08-08

Start date

2011-09-12

Completion date

2012-09-06

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this study is to investigate the usability of serum neutrophil gelatinase-associated lipocalin (NGAL) level as a diagnostic and/or prognostic biomarker, in patients with colorectal cancer (CRC) or precancerous lesion.

Interventions

Colon cancer screening; Studies on tissue samples have shown that NGAL expression increases in CRCs and inflammatory bowel diseases. This study is planned to investigate the usability of serum NGAL level as a diagnostic and/or prognostic biomarker, in patients with colorectal cancer. NGAL level was determined through serum samples. Blood was taken from each patient only once, before polypectomy (for the polip group) or surgery (for the cancer group).

Study design

Allocation

Non-randomised trial

Intervention model

Parallel

Primary purpose

Diagnosis

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Patients with colorectal carsinoma Patients with colorectal polyps without carcinoma Control group (patients whose colonoscopy examinations revealed no pathology named as control group)

Exclusion criteria

Active infection Renal failure Other organs cancer Detection of less than 12 lymph nodes Patients treated with neoadjuvant chemotherapy Blood samples with hemolysis

Outcome results